Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
Dela Cruz Chuh J, Go M, Chen Y, Guo J, Rafidi H, Mandikian D, Sun Y, Lin Z, Schneider K, Zhang P, Vij R, Sharpnack D, Chan P, de la Cruz C, Sadowsky J, Seshasayee D, Koerber JT, Pillow TH, Phillips GD, Rowntree RK, Boswell CA, Kozak KR, Polson AG, Polakis P, Yu SF, Dragovich PS, Agard NJ. Dela Cruz Chuh J, et al. Among authors: de la cruz c. MAbs. 2021 Jan-Dec;13(1):1862452. doi: 10.1080/19420862.2020.1862452. MAbs. 2021. PMID: 33382956 Free PMC article.
Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State.
Daemen A, Liu B, Song K, Kwong M, Gao M, Hong R, Nannini M, Peterson D, Liederer BM, de la Cruz C, Sangaraju D, Jaochico A, Zhao X, Sandoval W, Hunsaker T, Firestein R, Latham S, Sampath D, Evangelista M, Hatzivassiliou G. Daemen A, et al. Among authors: de la cruz c. Cell Metab. 2018 Sep 4;28(3):383-399.e9. doi: 10.1016/j.cmet.2018.06.003. Epub 2018 Jun 28. Cell Metab. 2018. PMID: 30043751 Free article.
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.
Hegde GV, de la Cruz CC, Chiu C, Alag N, Schaefer G, Crocker L, Ross S, Goldenberg D, Merchant M, Tien J, Shao L, Roth L, Tsai SP, Stawicki S, Jin Z, Wyatt SK, Carano RA, Zheng Y, Sweet-Cordero EA, Wu Y, Jackson EL. Hegde GV, et al. Among authors: de la cruz cc. Sci Transl Med. 2013 Feb 6;5(171):171ra18. doi: 10.1126/scitranslmed.3004438. Sci Transl Med. 2013. PMID: 23390248
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.
Jin L, Garcia J, Chan E, de la Cruz C, Segal E, Merchant M, Kharbanda S, Raisner R, Haverty PM, Modrusan Z, Ly J, Choo E, Kaufman S, Beresini MH, Romero FA, Magnuson S, Gascoigne KE. Jin L, et al. Among authors: de la cruz c. Cancer Res. 2017 Oct 15;77(20):5564-5575. doi: 10.1158/0008-5472.CAN-17-0314. Epub 2017 Aug 17. Cancer Res. 2017. PMID: 28819026
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
Daemen A, Cooper JE, Myrta S, Wongchenko MJ, Lin E, Long JE, Foreman O, Modrusan Z, Tremayne JR, de la Cruz CC, Merchant M, Martin SE, Yan Y, Junttila MR. Daemen A, et al. Among authors: de la cruz cc. Clin Cancer Res. 2021 Feb 15;27(4):1162-1173. doi: 10.1158/1078-0432.CCR-20-1835. Epub 2020 Oct 6. Clin Cancer Res. 2021. PMID: 33023953
Mutation position is an important determinant for predicting cancer neoantigens.
Capietto AH, Jhunjhunwala S, Pollock SB, Lupardus P, Wong J, Hänsch L, Cevallos J, Chestnut Y, Fernandez A, Lounsbury N, Nozawa T, Singh M, Fan Z, de la Cruz CC, Phung QT, Taraborrelli L, Haley B, Lill JR, Mellman I, Bourgon R, Delamarre L. Capietto AH, et al. Among authors: de la cruz cc. J Exp Med. 2020 Apr 6;217(4):e20190179. doi: 10.1084/jem.20190179. J Exp Med. 2020. PMID: 31940002 Free PMC article.
NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma.
Hegde GV, de la Cruz C, Giltnane JM, Crocker L, Venkatanarayan A, Schaefer G, Dunlap D, Hoeck JD, Piskol R, Gnad F, Modrusan Z, de Sauvage FJ, Siebel CW, Jackson EL. Hegde GV, et al. Among authors: de la cruz c, de sauvage fj. Elife. 2019 May 30;8:e46551. doi: 10.7554/eLife.46551. Elife. 2019. PMID: 31144617 Free PMC article.
Intratumoral Heterogeneity: From Diversity Comes Resistance.
Pribluda A, de la Cruz CC, Jackson EL. Pribluda A, et al. Among authors: de la cruz cc. Clin Cancer Res. 2015 Jul 1;21(13):2916-23. doi: 10.1158/1078-0432.CCR-14-1213. Epub 2015 Apr 2. Clin Cancer Res. 2015. PMID: 25838394 Review.
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
Fischer H, Ullah M, de la Cruz CC, Hunsaker T, Senn C, Wirz T, Wagner B, Draganov D, Vazvaei F, Donzelli M, Paehler A, Merchant M, Yu L. Fischer H, et al. Among authors: de la cruz cc. Neuro Oncol. 2020 Jun 9;22(6):819-829. doi: 10.1093/neuonc/noaa052. Neuro Oncol. 2020. PMID: 32383735 Free PMC article.
198 results